Spring '21 Publications in High Impact Factor Journals

Publications in Journals with an Impact Factor of 10.0 or Greater
 

1. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
   Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE 2nd, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, Ashley DM.
   Nat Commun. 2021;12(1):352.
    

2. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.
   Montefiori DC, Filsinger Interrante MV, Bell BN, Rubio AA, Joyce JG, Shiver JW, LaBranche CC, Kim PS.
   Proc Natl Acad Sci U S A. 2021;118(3):e2018027118.
    

3. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.
   Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee FH, Rando J, Bonsignori M, Hwang KK, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy AI, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang GY, Geng H, Lin BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond DD, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM.
   Science. 2021;371(6525):eabd2638.
    

4. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization.
   Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber B, Montefiori DC.
   Cell Host Microbe. 2021;29(1):23-31.e4.
    

5. Cold sensitivity of the SARS-CoV-2 spike ectodomain.
   Edwards RJ, Mansouri K, Stalls V, Manne K, Watts B, Parks R, Janowska K, Gobeil SMC, Kopp M, Li D, Lu X, Mu Z, Deyton M, Oguin TH 3rd, Sprenz J, Williams W, Saunders KO, Montefiori DC, Sempowski GD, Henderson R, Munir Alam S, Haynes BF, Acharya P.
   Nat Struct Mol Biol. 2021;28(2):128-131.
    

6. Isoforms of GPCR proteins combine for diverse signalling.
   Snyder JC, Rajagopal S.
   Nature. 2020;587(7835):553-554.
    

7. The role of neoadjuvant chemotherapy in patients with resectable malignant pleural mesothelioma-an institutional and national analysis.
   Voigt SL, Raman V, Jawitz OK, Bishawi M, Yang CJ, Tong BC, D'Amico TA, Harpole DH.
   J Natl Cancer Inst. 2020;112(11):1118-1127.
    

8. Does MRI-guided TULSA provide a targeted approach to ablation?
   Arcot R, Polascik TJ.
   Nat Rev Urol. 2021;18(1):5-6.
    

9. If the patient Is frail, emergency abdominal surgery is high risk.
   Kazaure HS, Lidsky ME, Lagoo-Deenadayalan SA.
   JAMA Surg. 2021;156(1):74-75.
    

10. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G.
    J Clin Invest. 2020;130(10):5157-5170.
     

11. Modeling early stage atherosclerosis in a primary human vascular microphysiological system.
    Zhang X, Bishawi M, Zhang G, Prasad V, Salmon E, Breithaupt JJ, Zhang Q, Truskey GA.
    Nat Commun. 2020;11(1):5426.
     

12. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.
    Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM.
    Nat Mater. 2020 Nov 30. doi: 10.1038/s41563-020-00849-5. Online ahead of print.
     

13. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial.
    Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM; National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O’Mara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks D.
    JAMA. 2020;324(21):2165-2176.
     

14. SIV infection duration largely determines broadening of neutralizing antibody response in macaques.
    Wu F, Ourmanov I, Kirmaier A, Leviyang S, LaBranche C, Huang J, Whitted S, Matsuda K, Montefiori D, Hirsch VM.
    J Clin Invest. 2020;130(10):5413-5424.
     

15. Surgical aortic valve replacement for failed TAVR prostheses: one more piece of the puzzle.
    Jawitz OK.
    J Am Coll Cardiol. 2020;76(16):1860-1861.
     

16. Oncologic outcomes after neoadjuvant chemotherapy and postmastectomy breast reconstruction.
    Fayanju OM, Hollenbeck ST, Greenup RA.
    JAMA Surg. 2020;155(12):1150-1151.
     

17. Biomarkers enhance discrimination and prognosis of type 2 myocardial infarction.
    Horiuchi Y, Wettersten N, Patel MP, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, Nowak RM, Vilke GM, Daniels LB, Hollander JE, Apple FS, Cannon CM, Nagurney JT, Schreiber D, deFilippi C, Hogan C, Diercks DB, Headden G, Limkakeng AT Jr, Anand I, Wu AHB, Ebmeyer S, Jaffe AS, Peacock WF, Maisel A.
    Circulation. 2020;142(16):1532-1544.
     

18. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice.
    Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tombácz I, Arwood L, Nachbagauer R, Karikó K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N.
    Immunity. 2020;53(4):724-732.e7.
     

19. Bioengineered human blood vessels.
    Niklason LE, Lawson JH.
    Science. 2020 Oct 9;370(6513):eaaw8682.
     

20. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM.
    J Clin Invest. 2020;130(11):5721-5737.
     

21. Surgical management of high-risk, localized prostate cancer.
    Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YA.
    Nat Rev Urol. 2020;17(12):679-690.
     

22. Geographic access to transcatheter aortic valve replacement centers in the United States: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.
    Marquis-Gravel G, Stebbins A, Kosinski AS, Cox ML, Harrison JK, Hughes GC, Thourani VH, Gleason TG, Kirtane AJ, Carroll JD, Mack MJ, Vemulapalli S.
    JAMA Cardiol. 2020;5(9):1006-1010.
     

23. Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury.
    Rowell SE, Meier EN, McKnight B, Kannas D, May S, Sheehan K, Bulger EM, Idris AH, Christenson J, Morrison LJ, Frascone RJ, Bosarge PL, Colella MR, Johannigman J, Cotton BA, Callum J, McMullan J, Dries DJ, Tibbs B, Richmond NJ, Weisfeldt ML, Tallon JM, Garrett JS, Zielinski MD, Aufderheide TP, Gandhi RR, Schlamp R, Robinson BRH, Jui J, Klein L, Rizoli S, Gamber M, Fleming M, Hwang J, Vincent LE, Williams C, Hendrickson A, Simonson R, Klotz P, Sopko G, Witham W, Ferrara M, Schreiber MA.
    JAMA. 2020;324(10):961-974.
     

24. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR, Stieh DJ, Sarnecki M, Walsh SR, Tomaras GD, Kublin JG, McElrath MJ, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert P, Edupuganti S, Karita E, Langedijk JP, Wegmann F, Corey L, Pau MG, Barouch DH, Schuitemaker H, Tomaka F; Traverse/HVTN 117/HPX2004 Study Team.
    Lancet HIV. 2020;7(10):e688-e698.
     

25. Challenges and novel therapies for vascular access in haemodialysis.
    Lawson JH, Niklason LE, Roy-Chaudhury P.
    Nat Rev Nephrol. 2020;16(10):586-602.
     

26. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus.
    Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI; Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC.
    Cell. 2020;182(4):812-827.e19.